Neu differentiation factor (NDF/heregulin) is secreted by ras-transformed cells and elevates tyrosine phosphorylation of the neu-encoded receptor kinase. Evidence from animal model systems and clinical observations suggest that overexpression of the neu/erbB-2 proto-oncogene may contribute to carcinoma development in humans. In vitro, NDF, as well as certain tumor-inhibitory monoclonal antibodies to p185neu, induce growth-arrest and differentiation of certain mammary tumor cells. This raises the possibility that mAb- or ligand-mediated effects may reverse the transformed phenotype through interaction with the oncogene product. Here we propose to experimentally test this intriguing possibility on the basis of a comprehensive biological study of NDF. Ectopic expression of wild-type and mutant NDF molecules will test the mitogenic versus differentiation potential of the factor, and correlate the domain structure of the precursor molecule with specific cellular functions. Preliminary in situ hybridization analysis and chromosomal mapping will be extended in order to guide later experiments that will address the physiological role of NDF by using gene targeting and inhibitory mAbs. The latter will be used also to assay NDF in body fluids in an attempt to correlate its expression with physiological disorders. Lastly, the mechanism of signal transduction by NDF will be analyzed. This includes the identification of a co-receptor of Neu whose existence was inferred by recent experiments, and characterization of the intracellular targets and processing of NDF-Neu complexes. Vectors that direct the synthesis of anti-sense RNA, or negative dominant mutants of p185neu, will be expressed in human tumor cells in order to test the role of Neu in maintaining the malignant state. Independent of this genetic approach, the effect of NDF and mAbs to Neu will be tested on cultured tumor cells and their xenografts in athymic mice. If successful, our later experiments will employ growth inhibitory combinations of NDF with various modified mAbs. Combinely, these studies are expected to shed light on the physiology of NDF and the neu gene, and their relevance to cancer development. They may further yield novel strategies and molecular tools that will help to control the growth of human carcinoma cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA051712-04
Application #
3196343
Study Section
Pathology B Study Section (PTHB)
Project Start
1990-05-01
Project End
1996-07-31
Budget Start
1993-08-04
Budget End
1994-07-31
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Weizmann Institute of Science
Department
Type
DUNS #
City
Rehovot
State
Country
Israel
Zip Code
76100
Pinkas-Kramarski, R; Lenferink, A E; Bacus, S S et al. (1998) The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene 16:1249-58
Klapper, L N; Vaisman, N; Hurwitz, E et al. (1997) A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14:2099-109
Levkowitz, G; Klapper, L N; Tzahar, E et al. (1996) Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12:1117-25
Pinkas-Kramarski, R; Shelly, M; Glathe, S et al. (1996) Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 271:19029-32
Tzahar, E; Waterman, H; Chen, X et al. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-87
Marikovsky, M; Lavi, S; Pinkas-Kramarski, R et al. (1995) ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene 10:1403-11
Gilboa, L; Ben-Levy, R; Yarden, Y et al. (1995) Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. J Biol Chem 270:7061-7
Karunagaran, D; Tzahar, E; Liu, N et al. (1995) Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases. J Biol Chem 270:9982-90
Ben-Baruch, N; Yarden, Y (1994) Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors. Proc Soc Exp Biol Med 206:221-7
Ben-Levy, R; Paterson, H F; Marshall, C J et al. (1994) A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 13:3302-11

Showing the most recent 10 out of 24 publications